@article{bb2e81d32f89441dbd1e6871d96f0851,
title = "EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer: Breast Cancer Research",
abstract = "Background: Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluated the efficacy of two different doses of weekly nab-paclitaxel, with a specific focus on their corresponding impact on patient function, in order to address the lack of data specifically relating to the older population. Methods: EFFECT is an open-label, phase II trial wherein 160 women with advanced breast cancer aged ≥ 65 years were enrolled from 15 institutions within Italy. Patients were randomly assigned 1:1 to receive nab-paclitaxel 100 mg/m2 (arm A) or 125 mg/m2 (arm B) on days 1, 8, and 15 on a 28-day cycle, as first-line treatment for advanced disease. The primary endpoint was event-free survival (EFS), wherein an event was defined as disease progression (PD), functional decline (FD), or death. In each arm, the null hypothesis that the median EFS would be ≤ 7 months was tested against a one-sided alternative according to the Brookmeyer Crowley test. Secondary endpoints included objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Results: After a median follow-up of 32.6 months, 140 events were observed in 158 evaluable patients. Median EFS was 8.2 months (90% CI, 5.9-8.9; p = 0.188) in arm A vs 8.3 months (90% CI, 6.2-9.7, p = 0.078) in arm B. Progression-free survival, overall survival, and response rates were similar in both groups. A higher percentage of dose reductions and discontinuations due to adverse events (AEs) was noted in arm B. The most frequently reported non-haematological AEs were fatigue (grade [G] 2-3 toxicity occurrence in arm A vs B, 43% and 51%, respectively) and peripheral neuropathy (G2-3 arm A vs B, 19% and 38%, respectively). Conclusion: Pre-specified outcomes were similar in both treatment arms. However, 100 mg/m2 was significantly better tolerated with fewer neurotoxicity-related events, representing a more feasible dose to be recommended for older patients with advanced disease. Trial registration: EudraCT, 2012-002707-18. Registered on June 4, 2012. NIH ClinicalTrials.gov, NCT02783222. Retrospectively registered on May 26, 2016. {\textcopyright} 2020 The Author(s).",
keywords = "Breast cancer, Functional decline, Metastatic, Nab-paclitaxel, Older adults, Toxicity, paclitaxel, 130-nm albumin-bound paclitaxel, albuminoid, antineoplastic agent, aged, alopecia, anemia, arthralgia, Article, bone marrow toxicity, breast cancer, Brookmeyer Crowley test, cancer mortality, clinical assessment tool, controlled study, daily life activity, diarrhea, disease exacerbation, dose response, drug efficacy, drug safety, drug tolerability, dyspnea, event free survival, fatigue, febrile neutropenia, female, follow up, functional decline, geriatrics, human, infection, instrumental activity of daily living, Italy, leukopenia, liver toxicity, major clinical study, multiple cycle treatment, myalgia, nausea and vomiting, nephrotoxicity, neurotoxicity, neutropenia, null hypothesis, objective response rate, open study, overall survival, peripheral neuropathy, phase 2 clinical trial, primary health care, progression free survival, randomized controlled trial, survival time, treatment response, age, breast tumor, cancer staging, clinical trial, multicenter study, pathology, prognosis, survival rate, tumor invasion, very elderly, Age Factors, Aged, Aged, 80 and over, Albumins, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Dose-Response Relationship, Drug, Female, Humans, Neoplasm Invasiveness, Neoplasm Staging, Paclitaxel, Prognosis, Survival Rate",
author = "L. Biganzoli and S. Cinieri and R. Berardi and R. Pedersini and A. McCartney and A.M. Minisini and E.R. Caremoli and S. Spazzapan and E. Magnolfi and A. Brunello and E. Risi and R. Palumbo and S. Leo and M. Colleoni and S. Donati and {De Placido}, S. and L. Orlando and M. Pistelli and V. Parolin and A. Mislang and D. Becheri and F. Puglisi and G. Sanna and E. Zafarana and L. Boni and G. Mottino",
note = "Export Date: 1 March 2021 CODEN: BCRRC Correspondence Address: Biganzoli, L.; Sandro Pitigliani Department of Medical Oncology, Italy; email: laura.biganzoli@uslcentro.toscana.it Chemicals/CAS: paclitaxel, 33069-62-4; 130-nm albumin-bound paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Paclitaxel References: van Abbema, D.L., van Den Akker, M., Janssen-Heijnen, M.L., van Den Berkmortel, F., Hoeben, A., de Vos-Geelen, J., Buntinx, F., Patient- And tumor-related predictors of chemotherapy intolerance in older patients with cancer: a systematic review (2019) J Ger Oncol, 10 (1), pp. 31-41; Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) (2012) Lancet Oncol, 13 (4), pp. e148-e160. , 22469125; Biganzoli, L., Aapro, M., Loibl, S., Wildiers, H., Brain, E., Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG Task Force (2016) Cancer Treat Rev, 43, pp. 19-26. , 1:CAS:528:DC%2BC2MXitVansL7I 26827689; Biganzoli, L., Licitra, S., Moretti, E., Pestrin, M., Zafarana, E., Di Leo, A., Taxanes in the elderly: can we gain as much and be less toxic? (2009) Crit Rev Oncol Hematol, 70 (3), pp. 262-271. , 18762431; Lichtman, S.M., Hurria, A., Cirrincione, C.T., Seidman, A.D., Winer, E., Hudis, C., Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 (2012) Ann Oncol, 23 (3), pp. 632-638. , 1:STN:280:DC%2BC38rgvFWqtQ%3D%3D 21693770; Luciani, A., Jacobsen, P.B., Extermann, M., Foa, P., Marussi, D., Overcash, J.A., Balducci, L., Fatigue and functional dependence in older cancer patients (2008) Am J Clin Oncol, 31 (5), pp. 424-430. , 10.1097/COC.0b013e31816d915f 18838877; Kenis, C., Decoster, L., Bastin, J., Functional decline in older patients with cancer receiving chemotherapy: a multicenter prospective study (2017) J Geriatr Oncol, 8 (3), pp. 196-205. , 10.1016/j.jgo.2017.02.010 28330581; Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer (2005) J Clin Oncol, 23 (31), pp. 7794-7803. , 1:CAS:528:DC%2BD2MXht1Cqs7nK 16172456; Gradishar, W.J., Krasnojon, D., Cheporov, S., Makhson, A.N., Manikhas, G.M., Clawson, A., Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer (2009) J Clin Oncol, 27 (22), pp. 3611-3619. , 1:CAS:528:DC%2BD1MXhtVOnu7nE 19470941; Liu, Y., Ye, G., Yan, D., Zhang, L., Fan, F., Feng, J., Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials (2017) Oncotarget., 8 (42), pp. 72950-72958. , 29069839 5641182; Aapro, M., Tjulandin, S., Bhar, P., Gradishar, W., Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis (2011) Breast., 20 (5), pp. 468-474. , 21843943; Miller, M.D., Paradis, C.F., Houck, P.R., Mazumdar, S., Stack, J.A., Rifai, A.H., Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale (1992) Psychiatry Res, 41 (3), pp. 237-248. , 1:STN:280:DyaK383nvFCntw%3D%3D 1594710; Katz, S., Downs, T.D., Cash, H.R., Grotz, R.C., Progress in development of the index of ADL (1970) Gerontologist., 10 (1), pp. 20-30. , 1:STN:280:DyaE3c3gs1OgsQ%3D%3D 5420677; Lawton, M.P., Brody, E.M., Assessment of older people: self-maintaining and instrumental activities of daily living (1969) Gerontologist., 9 (3), pp. 179-186. , 1:STN:280:DyaE3c%2FivV2kug%3D%3D 5349366; Brookmeyer, R., Crowley, J., A confidence interval for the median survival time (1982) Biometrics., 38 (1), p. 29; Blum, J.L., Savin, M.A., Edelman, G., Pippen, J.E., Robert, N.J., Geister, B.V., Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes (2007) Clin Breast Cancer., 7 (11), pp. 850-856. , 1:CAS:528:DC%2BD1cXhtlynt7s%3D 18269774; Bossi, P., Antonuzzo, A., Cherny, N.I., Rosengarten, O., Pernot, S., Trippa, F., Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines (2018) Ann Oncol, 29 (SUPP 4), pp. iv126-iv142. , 1:STN:280:DC%2BB3c%2Fgs1Oqtw%3D%3D 32169222; (2018) NCCN Clinical Practice Guidelines in Oncology. Older adult oncology. Version 1. 2018, , https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf, Network NCC; Trifan, A., Stanciu, C., Girleanu, I., Stoica, O.C., Singeap, A.M., Maxim, R., Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis (2017) World J Gastroenterol, 23 (35), pp. 6500-6515. , 1:CAS:528:DC%2BC1cXitFaiur7E 29085200 5643276; Neemann, K., Freifeld, A., Clostridium difficile-associated diarrhea in the oncology patient (2017) J Oncol Pract, 13 (1), pp. 25-30. , 28084880; Hurria, A., Soto-Perez-De-Celis, E., Blanchard, S., Burhenn, P., Yeon, C.H., Yuan, Y., A phase II trial of older adults with metastatic breast cancer receiving nab-paclitaxel: melding the fields of geriatrics and oncology (2019) Clin Breast Cancer, 19 (2), pp. 89-96. , 10.1016/j.clbc.2018.10.002 1:CAS:528:DC%2BC1cXitVKhsL3M 30503309; Smorenburg, C.H., de Groot, S.M., van Leeuwen-Stok, A.E., Hamaker, M.E., Wymenga, A.N., de Graaf, H., A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG (2014) Ann Oncol, 25 (3), pp. 599-605. , 1:STN:280:DC%2BC2cvivVaisg%3D%3D 24504445 4433520; Ten Tije, A.J., Smorenburg, C.H., Seynaeve, C., Sparreboom, A., Schothorst, K.L.C., Kerkhofs, L.G.M., Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial (2004) Eur J Cancer, 40 (3), pp. 352-357. , 14746852; Del Mastro, L., Perrone, F., Repetto, L., Manzione, L., Zagonel, V., Fratino, L., Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer) (2005) Ann Oncol, 16, pp. 253-258. , 15668279; Pallis, A.G., Ring, A., Fortpied, C., Penninckx, B., Van Nes, M.C., Wedding, U., EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors (2011) Ann Oncol, 22 (8), pp. 1922-1926. , 10.1093/annonc/mdq687 1:STN:280:DC%2BC3MfisVaisw%3D%3D 21266517; Hurria, A., Levit, L.A., Dale, W., Mohile, S.G., Muss, H.B., Fehrenbacher, L., Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement (2015) J Clin Oncol, 33 (32), pp. 3826-3833. , 10.1200/JCO.2015.63.0319 26195697",
year = "2020",
doi = "10.1186/s13058-020-01319-1",
language = "English",
volume = "22",
journal = "Breast Cancer Res.",
issn = "1465-5411",
publisher = "BioMed Central",
number = "1",
}